TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04385537

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PECAN
Description: Raw pecan halves without other changes to their habitual diet.
Study: NCT00196326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-1011
Description: Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
Study: NCT04365933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha2a
Description: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha2a
Description: Subcutaneous
Study: NCT04226040

Intervention type: BEHAVIORAL
Intervention: DOW and illness perception
Description: Acutely ill patients are exposed to a survey regarding their degree of worry and illness perception
Study: NCT03867682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lintuzumab-Ac225
Description: In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
Study: NCT01242566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: orally 150-200 mg/m2/day for 5 consecutive days every 4 week
Study: NCT04435990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10,000 MM09
Description: Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30,000 MM09
Description: Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous
Description: The same solution and presentation as the active treatment, but without active ingredients.
Study: NCT02186717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Patients will be asked to chew gum three times a day for 30 minutes each time
Study: NCT01510379

Intervention type: DRUG
Group type: OTHER
Intervention: IV promethazine 25 mg q 6 hours prn

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV promethazine 25 mg q 6 hours prn

Intervention type: DRUG
Group type: OTHER
Intervention: Elixir promethazine 25 mg q 6 hours prn after discharge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elixir promethazine 25 mg q 6 hours prn after discharge
Study: NCT03166215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-935
Description: TAK-935 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-935 placebo-matching tablets.
Study: NCT01662713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI
Description: Imaging of skin
Study: NCT04491760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
Study: NCT03024723

Intervention type: DEVICE
Intervention: nasal mask CPAP
Description: CPAP and ventilation administered via nasal mask
Study: NCT01543789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal mesh placement
Description: Mesh placement inside the peritoneal cavity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preperitoneal mesh placement
Description: Mesh placement between peritoneum and muscle layer.
Study: NCT02030990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Description: 0.01% applied to cornea with a sponge during PRK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Description: 0.01% applied to cornea with a sponge during PRK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 1% topical ocular steroid
Description: topical steroid drops applied to the cornea after PRK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 1% topical ocular steroid
Description: topical steroid drops applied to the cornea after PRK

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorometholone 1% topical ocular steroid
Description: topical steroid drops applied to the cornea after PRK
Study: NCT00892138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: 7 week course modeled on MBSR according to Kabat-Zinn
Study: NCT03408210

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow and lymphoid irradiation
Description: Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0.
Study: NCT02504931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
Study: NCT00054028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01742689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin intranasal spray
Description: 10 microgram per puff, 40 microgram is Descript

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intranasal spray
Description: Saline spray identical to desmopressin, administered as 4 sprays
Study: NCT00791518

Intervention type: DRUG
Intervention: No intervention
Description: No intervention
Study: NCT01742689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository
Description: Indomethacin suppository 100 milligram single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin suppository
Description: Indomethacin suppository 100 milligram single dose
Study: NCT01867138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Study: NCT02231385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetic Acid
Description: Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time.
Study: NCT02964585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 16 weeks
Study: NCT02591368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligament reconstruction tendon interposition
Description: In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suspensionplasty with one-suture construct
Description: In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suspensionplasty with two-suture construct
Description: In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
Study: NCT01761500

Intervention type: OTHER
Group type: OTHER
Intervention: Modified BFM-90 protocol
Description: Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
Study: NCT01416623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: henatinib
Description: Henatinib Maleate Tablets
Study: NCT01595594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Doxycycline and Sham aPDT
Description: It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aPDT + Doxycycline Placebo
Description: The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
Study: NCT01754792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pinitol
Description: Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pinitol
Description: Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pinitol
Description: Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
Study: NCT03999086

Intervention type: PROCEDURE
Intervention: Intervention
Description: We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion

Intervention type: OTHER
Intervention: Control Group
Description: Laboratory analysis to guide transfusion
Study: NCT03861156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0316
Description: Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
Study: NCT01994993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin and metronidazole and gentamicin
Description: IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin and gentamicin and clindamycin
Description: IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin and Piperacillin- tazobactam
Description: IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care antibiotics and metronidazole
Description: IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole, clindamycin, or piperacillin-tazobactam
Description: IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study: NCT00499746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol
Description: oral dose, once per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral dose, once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: oral dose, once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: oral dose, once per day
Study: NCT02273960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004 75 mg IV
Description: BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004 225 mg IV
Description: BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004 675 mg IV
Description: BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004 1500 mg IV
Description: BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
Study: NCT03514901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental combination beyond Focal Progression
Description: Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab or Nivolumab
Description: Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
Study: NCT01070108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
Study: NCT02009631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib (ABT-888)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib (ABT-888)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01050257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir IV
Description: Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir IV
Description: Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir IV
Description: Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir Oral
Description: Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir Oral
Description: Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir Oral
Description: Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
Study: NCT05023746

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetron lung cancer panel
Description: Follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with Genetron lung cancer panel and comparison methods. The detection results are compared, and the samples that are inconsistent with the detection results of similar products on the market are reviewed by the the Sanger sequencing method, when the site detection results compared with Sanger sequencing method are inconsistent, Sanger's detection results are recognized. The results were determined independently according to the cutoff values or interpretation requirements provided by each method, and relevant statistics were used to evaluate clinical application performance of Genetron lung cancer panel.
Study: NCT00584558

Intervention type: PROCEDURE
Intervention: Catheter Ablation
Description: Catheter Ablation of arrhythmias